TriSalus: 3 Key Takeaways for Long-Term Investors
Sales rep productivity in new territories is running behind plan, so the growth case hinges on whether those reps catch up.
TriSalus (TLSI -11.49%) reported third-quarter 2026 revenue of $12.9 million, missing internal targets due to sales team productivity delays and shifting treatment patterns. However, the company doubled its sales force to capture a $2.5 billion market for pressure-enabled drug delivery (PEDD), and CMS finalized national pricing for outpatient procedures and PEDD embolization in the physician office setting, providing a clear payment path.
Gross margin for the quarter improved to 86%, driven by lower average unit cost of TriNav and continuous manufacturing improvements.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
